This is the first description of an acquired, hematopoietic cell-intrinsic, pathogenic HAVCR2 mutation associated with TIM-3 deficiency in blood-derived and intestinal immune cells clinically linked with post-aSCT IBD. This evidence concerns the gene HAVCR2 and inflammatory bowel disease.